<DOC>
	<DOCNO>NCT00057642</DOCNO>
	<brief_summary>This study develop intervention increase retention Hispanics major depression antidepressant therapy .</brief_summary>
	<brief_title>Improving Retention Hispanics Receiving Antidepressant Therapy</brief_title>
	<detailed_description>Despite major advance treatment psychiatric disorder , Hispanics continue underutilize mental health service relative mental health need . Cultural factor important cause underutilization . To date , however , attempt boost utilization improve cultural congruence psychiatric service focus retain Hispanics antidepressant therapy . Motivational Interviewing ( MI ) time-limited psychotherapy successfully improve treatment retention among patient dually diagnose substance abuse psychiatric disorder . During Phase I study , MI adapt use adjunctive therapy antidepressant treatment culturally adapt Hispanic participant . In Phase II , participant receive sertraline 12 week participate four session MI therapy supplementary intervention design encourage treatment retention . Participants intolerant sertraline inadequate response Week 6 switch venlafaxine ER continue receive MI complete study assessment . A follow-up interview conduct 6 month termination treatment .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Diagnostic Statistical Manual , 4th edition criterion Major Depressive Disorder Patients selfidentify Hispanic Spanishdominant , Englishdominant , bilingual Acceptable method contraception Hamilton Depression Rating Scale score &gt; = 18 Visit 1 Sertraline venlafaxine ER clinically appropriate History schizophrenia , bipolar affective disorder , schizoaffective disorder , depression psychotic symptom , organic brain syndrome DSMIV criterion alcohol substance abuse dependence 6 month prior screen Pregnancy breastfeed At risk commit suicide Clinically significant renal , pulmonary , cerebrovascular , cardiovascular , gastrointestinal , endocrine disorder Glaucoma , history increase intraocular pressure ( IOP ) , risk increase IOP Untreated unstable hypertension Clinically significant laboratory abnormality abnormal electrocardiogram Medical condition might interfere process drug absorption , metabolism , elimination Clinically significant thyroid dysfunction ( except patient stable asymptomatic thyroid replacement therapy ) Current past history seizure disorder ( except febrile seizure childhood ) History fail sertraline venlafaxine treatment least 4 week adequate dos Allergy hypersensitivity sertraline venlafaxine History two fail selective serotonin reuptake inhibitor ( SSRI ) trial major depression adequate dos duration Monoamine oxidase inhibitor ( MAOIs ) fluoxetine within 4 week prior screen , SSRIs , antidepressant , neuroleptic , mood stabilizer , buspirone , benzodiazepine , psychotropic drug ( except zolpidem insomnia ) within 2 week prior screen Electroconvulsive Therapy ( ECT ) within last 3 month Effective medication psychotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Hispanic Americans</keyword>
</DOC>